Fecal microbiota transplantation in combination with immune checkpoint blockade in patients with advanced melanoma: A randomized phase II trial

粪便微生物群移植联合免疫检查点阻断治疗晚期黑色素瘤患者：一项随机 II 期试验

• 批准号: 490062
• 负责人: Dancey Janet E
• 金额: $ 130.13万
• 依托单位: Queen's University (Kingston, Ontario)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2023
• 资助国家: 加拿大
• 起止时间: 2023-09-01 至 2028-03-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=490062&lang=en
• 关键词: Fecal Microbiota Transplant; Melanoma; Microbiome; Multicentre; Phase Ii; Progression-Free Survival; Randomized Controlled Trial; Fecal Microbiota Transplant; Melanoma; Microbiome; Multicentre; Phase Ii; Progression-Free Survival; Randomized Controlled Trial

Cancer immunotherapy (IO) enables immune cells to recognize and kill melanoma cells improving the lives of patients. While IO is now the standard-of-care to treat melanoma, melanoma remains the leading cause of skin cancer-related death in Canada, and mos

癌症免疫疗法（IO）使免疫细胞能够识别并杀死黑色素瘤细胞改善患者的生活。尽管IO现在是治疗黑色素瘤的护理标准，但黑色素瘤仍然是加拿大皮肤癌相关死亡的主要原因，MOS